Pharma BD Deal Intelligence
AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate. AstraZeneca will pay $1 billion upfront in staged…
AstraZeneca and Daiichi Sankyo expanded their collaboration with a deal worth up to $6 billion for datopotamab deruxtecan, a TROP2-targeting ADC for lung and…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca and Daiichi Sankyo entered a global collaboration to jointly develop and commercialize datopotamab deruxtecan (DS-1062), a TROP2-directed antibody-drug conjugate. AstraZeneca paid $1 billion upfront in staged payments ($350M at execution, $325M at 12 months, $325M at 24 months) with up to $5 billion in regulatory and sales milestones. This was the second major AZ-Daiichi ADC collaboration following the 2019 Enhertu deal. Daiichi Sankyo retained exclusive rights in Japan.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Daiichi Sankyo Company, Limited (this deal) | 2020 | $6.0B | 62 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2020 deals · AstraZeneca PLC deals · Oncology deals